Site icon pharmaceutical daily

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: A Business, Stakeholder, Technology and Pipeline Analysis

BusinessWire

Mechanism of Action of KEYTRUDA (pembrolizumab): T-cell Reactivation Image: Keytruda.com

DUBLIN–(BUSINESS WIRE)–The “T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: A Business, Stakeholder, Technology and Pipeline Analysis” report has been added to ResearchAndMarkets.com’s offering.

This report provides you with a landscape description and analysis of T-cell and natural killer (NK) cell engaging bispecific antibodies as of June 2019. The report brings you up-to-date information about major pharmaceutical and technology companies active in the field, state of the art and emerging next generation technologies, subject and economic terms of partnering deals and a pipeline analysis of product candidates including clinical experiences.

Analysis is based on the profiles of 56 Big Pharma and technology companies covering company background/history, financial situation, technology overview, partnering activities and pipeline overview. 38 different technologies to create bispecific T-cell and NK cell engaging antibodies are profiled in depth. Pipeline analysis is based on the profiles of 90 drug candidates in development. Sources of information are 237 scientific references. Non-scientific sources of information, such as press releases, annual reports and presentations, are disclosed within the text with an embedded hyperlink leading to the online source of information.

Immunotherapy of cancer with T-cells oder NK cells is an area of great interest for the biopharmaceutical industry. Chimeric antigen receptor (CAR) engineered T-cell or NK cells represent one treatment modality under clinical evaluation, but the majority of Big Pharma prefers the engagement of T-cells or NK cells by recombinant monoclonal antibodies as off-the-shelf products. As only a few major pharmaceutical companies have clinically validated in-house bispecific antibody technology, partnering with technology providing companies is of great importance.

Within three years, the number of clinical stage T-cell and NK cell engagers has more than doubled and further product candidates will enter clinical evaluation in the near future.

This report will show you that there are plenty of opportunities for players in the field, including major pharmas, technology providers and investors.

This report will inform you about Big Pharma’s:

38 technology companies with T-cell and NK cell engaging bispecific antibody technologies are analyzed regarding their:

The profiles of 58 clinical stage and 25 non-clinical development stage T-cell and NK cell engaging bispecific antibodies form the basis of:

So far, the attrition rate of T-cell and NK cell engaging antibodies is relatively low (12%). This report identified the terminated bispecific T-cell engager projects and the reasons for discontinuation.

This report also analyzes the financial maturity of technology companies and their specific sources of funding. Overall, raising money for bispecific T-cell and NK cell engagers is no fundamental problem.

What will you find in the report?

Companies Mentioned

Key Topics Covered

1 Executive Summary

2 Introduction

3 Stakeholder & Technology Analysis of Major Pharmaceutical Companies

4 Stakeholder & Technology Analysis of Technology Companies

5 Pipeline Analysis of T-Cell & NK Cell Engaging Bispecific Antibodies

6 Sources of Financing & Partnering Deals of Technology Companies

7 Company Profiles

8 Technology Profiles

9 Drug & Drug Candidate Profiles

10 References

For more information about this report visit https://www.researchandmarkets.com/r/y6nrwe

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics: Biotechnology, Immune Disorders Drugs, Oncology Drugs

Exit mobile version